TY - JOUR
T1 - Restrictive transfusion strategy is more effective in massive burns
T2 - Results of the TRIBE multicenter prospective randomized trial
AU - Palmieri, Tina L.
AU - Holmes, James H.
AU - Arnoldo, Brett
AU - Peck, Michael
AU - Cochran, Amalia
AU - King, Booker T.
AU - Dominic, William
AU - Cartotto, Robert
AU - Bhavsar, Dhaval
AU - Tredget, Edward
AU - Stapelberg, Francois
AU - Mozingo, David
AU - Friedman, Bruce
AU - Sen, Soman
AU - Taylor, Sandra L.
AU - Pollock, Brad H.
N1 - Funding Information:
This study was funded by United States Army Medical Research and Materiel Command (USAMRMC) Award #W81XWH-08-1-0760 with support from the National Center for Research Resources, National Institutes of Health, through grant #UL1 RR024146, the National Center for Advancing Translational Sciences, National Institutes of Health, through grant #TR 000002. This supplement was sponsored by the Office of the Secretary of Defense for Health Affairs.
Publisher Copyright:
© 2019 Association of Military Surgeons of the United States. All rights reserved.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Objectives: Studies suggest that a restrictive transfusion strategy is safe in burns, yet the efficacy of a restrictive transfusion policy in massive burn injury is uncertain. Our objective: Compare outcomes between massive burn (.60% total body surface area (TBSA) burn) and major (20.59% TBSA) burn using a restrictive or a liberal blood transfusion strategy. Methods: Patients with burns .20% were block randomized by age and TBSA to a restrictive (transfuse hemoglobin 7 g/dL) or liberal (transfuse hemoglobin 10 g/dL) strategy throughout hospitalization. Data collected included demographics, infections, transfusions, and outcomes. Results: Three hundred and forty-five patients received 7,054 units blood, 2,886 in massive and 4,168 in restrictive. Patients were similar in age, TBSA, and inhalation injury. The restrictive group received less blood (45.57 } 47.63 vs. 77.16 ± 55.0, p 0.03 massive; 11.0 ± 16.70 vs. 16.78 ± 17.39, p 0.001) major). In massive burn, the restrictive group had fewer ventilator days (p > 0.05). Median ICU days and LOS were lower in the restrictive group; wound healing, mortality, and infection did not differ. No significant outcome differences occurred in the major (20.59%) group (p > 0.05). Conclusions:: A restrictive transfusion strategy may be beneficial in massive burns in reducing ventilator days, ICU days and blood utilization, but does not decrease infection, mortality, hospital LOS or wound healing.
AB - Objectives: Studies suggest that a restrictive transfusion strategy is safe in burns, yet the efficacy of a restrictive transfusion policy in massive burn injury is uncertain. Our objective: Compare outcomes between massive burn (.60% total body surface area (TBSA) burn) and major (20.59% TBSA) burn using a restrictive or a liberal blood transfusion strategy. Methods: Patients with burns .20% were block randomized by age and TBSA to a restrictive (transfuse hemoglobin 7 g/dL) or liberal (transfuse hemoglobin 10 g/dL) strategy throughout hospitalization. Data collected included demographics, infections, transfusions, and outcomes. Results: Three hundred and forty-five patients received 7,054 units blood, 2,886 in massive and 4,168 in restrictive. Patients were similar in age, TBSA, and inhalation injury. The restrictive group received less blood (45.57 } 47.63 vs. 77.16 ± 55.0, p 0.03 massive; 11.0 ± 16.70 vs. 16.78 ± 17.39, p 0.001) major). In massive burn, the restrictive group had fewer ventilator days (p > 0.05). Median ICU days and LOS were lower in the restrictive group; wound healing, mortality, and infection did not differ. No significant outcome differences occurred in the major (20.59%) group (p > 0.05). Conclusions:: A restrictive transfusion strategy may be beneficial in massive burns in reducing ventilator days, ICU days and blood utilization, but does not decrease infection, mortality, hospital LOS or wound healing.
KW - blood transfusion
KW - burn treatment
KW - infection
KW - outcomes
UR - http://www.scopus.com/inward/record.url?scp=85063675246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063675246&partnerID=8YFLogxK
U2 - 10.1093/milmed/usy279
DO - 10.1093/milmed/usy279
M3 - Article
C2 - 30371811
AN - SCOPUS:85063675246
SN - 0026-4075
VL - 184
SP - 11
EP - 15
JO - Military Medicine
JF - Military Medicine
ER -